Loading
Infections and Bacterial Resistance / Burkholderia Infections and Melioidosis · Journal article
Diagnostics · August 18, 2026
A consensus or society position rather than new primary data.
This narrative review summarizes the role of next-generation sequencing (metagenomic and whole-genome) in melioidosis diagnosis, outbreak investigation, and antimicrobial resistance detection. While the review identifies promise in reducing diagnostic delays and improving surveillance, it does not present new empirical evidence or quantify the clinical or epidemiological impact of NGS integration.
Narrative review. Patients with melioidosis and related environmental/epidemiological surveillance contexts; resource-limited settings mentioned..
Metagenomic NGS enables culture-independent detection of Burkholderia pseudomallei directly from clinical samples, addressing limitations of conventional culture and serology. Whole-genome sequencing provides outbreak tracing and source attribution from cultured isolates. Resistance profiling using NGS detects antimicrobial resistance determinants (e.g., penA mutations) to guide antimicrobial therapy.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and laboratory professionals should recognize NGS as a tool to reduce diagnostic delay in melioidosis through culture-independent detection and to support resistance-guided therapy. However, implementation decisions require consideration of cost, standardization, and local resources.
A narrative review synthesizing evidence on NGS applications in melioidosis diagnosis, epidemiology, and resistance surveillance, offering clinical and laboratory guidance without presenting new empirical data or a primary study result.
As stated by the source record.
Clinicians and laboratory professionals should recognize NGS as a tool to reduce diagnostic delay in melioidosis through culture-independent detection and to support resistance-guided therapy. However, implementation decisions require consideration of cost, standardization, and local resources.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Melioidosis, caused by Burkholderia pseudomallei, is a severe infectious disease with high mortality. Diagnostic delays due to conventional culture and serology limitations impact patient outcomes. This narrative review synthesizes evidence on next-generation sequencing (NGS) in melioidosis. NGS technologies encompass two main applications: metagenomic NGS (mNGS), which enables culture-independent detection directly from clinical samples, and whole-genome sequencing (WGS), which provides outbreak tracing and source attribution from cultured isolates. Resistance profiling detects antimicrobial resistance (AMR) determinants (e.g., penA mutations) to guide therapy. Recent 2025–2026 studies highlight new applications, including direct pathogen genome recovery from environmental samples. Despite cost and standardization challenges, integrating NGS into clinical workflows holds promise for improving melioidosis management, especially in resource-limited settings.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.